Repertoire Immune Medicines, a biotechnology company, has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease.

Under the terms of the agreement, Repertoire will lead target discovery activities using its DECODE platform to explore a large antigenic space, and Genentech will be responsible for preclinical and clinical development as well as the global commercialization of innovative therapies that incorporate the target discovery work.

Repertoire is eligible to receive $35M upfront as well as up to $730M in additional development, regulatory and commercial milestones, as well as tiered royalties.

“Repertoire’s DECODE platform uniquely maps the entire immune synapse in patients and thereby enables development of transformative T cell-targeted medicines for autoimmune diseases and cancer,” said Torben Straight Nissen, Chairman and CEO of Repertoire and Executive Partner at Flagship Pioneering. “The enormous breadth of DECODE’s therapeutic target discovery potential is well beyond what we could realize on our own. Given Genentech’s commitment and experience as the global market leader in developing treatments for autoimmune diseases, we are delighted to partner with them to bring medicines to patients that reset the immune system and have the potential to provide significant therapeutic benefits.”

Boris L. Zaïtra, Head of Roche Corporate Business Development, said, “As we seek new opportunities to bring an even greater impact to patients, we look forward to translating the new discoveries DECODE and the team at Repertoire will reveal to develop novel medicines for patients suffering from autoimmune diseases.”